CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Cortexyme (CRTX) stock forecast: Can the drug maker recover?

By Ryan Hogg

Edited by Jekaterina Drozdovica

07:57, 23 December 2021

Richmond, Virginia, USA - 8 May 2019: Illustrative Editorial of Cortexyme, Inc. website homepage. Cortexyme, Inc. logo visible on display screen.
Cortexyme (CRTX) stock forecast: Can the drug maker recover? – Photo: Shutterstock

Uncertainty abounds for Cortexyme (CRTX). Will a disappointing end to October have a lasting impact on the company?

The stock lost more than three quarters of its value following the failure of the Atuzaginstat drug in a Phase 3 trial. The price has since treaded water, with gains erased as quickly as they are added in the last two months. Can the stock recover? What factors are shaping the Cortexyme share price forecast?

Cortexyme went public on 9 May 2019 through an initial public offering (IPO). The pharmaceutical company is developing drugs to combat Alzheimer’s, Parkinson’s and COVID-19.

coretex

Cortexyme stock analysis after 76% crash

Since its market debut at £17 a share in 2019, Cotexyme has struggled. After reaching a record high of $120 on 10 August, the price action moved sideways to lower before crashing to $13.51 on 27 October on the back of the disappointing trial results and analysts’ downgrades. 

Since then the stock moved largely sideways, and is currently trading at $12.46 (as of 21 December), with a market cap of $372.28m.

Cortexyme all-time performance chart

Technical indicators are mixed for Cortexyme. One-day oscillators are slightly skewed towards ‘buy’, with the company’s Momentum and MACD Level giving bullish signals. The relative strength index (RSI) of 31.69 reflects an oversold or undervalued condition. 

Moving averages however give ‘strong sell’ signals, with 12 of the 15 metrics skewed towards sell. 

Disappointing clinical results

Cortexyme’s long-term success could be dependent on its ability to succeed in developing pharmaceutical treatments. This was evident on 27 October, when shares fell 76% in just one day after the pharma company announced that it had missed its goal in Phase 3 trials for Atuzaginstat, a possible treatment of Altzeihmer’s disease. 

The failure to discover an improvement in two measures of cognition for every patient enrolled in its study led to multiple analysts, including Bank of America, downgrading the stock, which lost more than $1.3bn of market cap value on the day. 

The Federal and Drug Administration (FDA) placed a clinical hold on the drug in February 2021.

The drug  racked up costs of $19.6m in the nine months to September 2021 and $32.9m in the same period for 2020. This limited investment in other drugs the company develops, none of which are beyond Phase 1.

CORTEXYME EXPANDING PIPELINE

In other Cortexyme stock news, shortly after the disappointing trial results, the company announced that Atuzaginstat showed a 30 - 50% slowing of cognitive decline when taken in a lower dose of 40mg. 

“Our ability to identify the right population in historically hard to treat mild to moderate Alzheimer’s patients, along with finding an efficacious dose with a differentiated safety profile, is important progress toward a breakthrough treatment for Alzheimer’s disease,” Michael Detke, Cortexyme’s chief medical officer, said in a press release.

Atuzaginstat is in a relatively small pool of researchers into Alzheimer’s treatments, with a review by the Translational Research and Clinical Interventions journal showing 152 clinical trials, as of 2021. 

The drug was in the biggest pool of Disease Modifying Treatments, but its progress to a more advanced stage should allow for short-term identification as to whether the drug can return revenues.

US100

16,001.20 Price
+0.470% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 7.0

BTC/USD

38,757.50 Price
+2.510% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

XRP/USD

0.62 Price
+0.890% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Gold

2,072.25 Price
+1.760% 1D Chg, %
Long position overnight fee -0.0193%
Short position overnight fee 0.0111%
Overnight fee time 22:00 (UTC)
Spread 0.30

If the latest results were indeed signs of positive developments in Cortexyme’s future research, it has not yet been priced in by investors, with the stock still trading close to its October lows. 

Latest results reveal consistent losses

Cortexyme remains a company in a growth phase, posting consistent losses in the expectation of strong future revenue streams, a strategy disrupted by disappointing clinical results for Atuzaginstat.

Latest earnings for the third quarter of 2021 revealed a $21.7m net loss, broadly in line with the figure for the same period last year. Earnings per share (EPS) came at -$0.73, in line with analysts’ estimates.

Research and development costs at $14.04m weighed heaviest on the company’s balance sheet, while general and administrative costs at $7.6m were up 55%.

Cortexyme’s deficit grew to $213.2m, following increasing losses between 2018 and 2020. With no drugs commercially available for sale, future losses now look likely to exceed the expectations of investors.

While Atuzaginstat remained the primary source of drug-development expense, its costs fell by 62.4%, while development costs of COR588, a potential treatment for periodontal disease, increased by 216%.

Cortexyme (CRTX) stock forecast

According to data gathered by Marketbeat, Cortexyme’s stock price predictions suggest a significant upside.

The average 12-month Cortexyme price target based on five analysts’ views currently sits at $38.50, ranging from the low of $15 to the high of $75.

The stock has a ‘hold’ consensus recommendation, with three analysts rating Cortexyme as a ‘buy’, one as a ‘hold’ and one giving a ‘sell’. 

Cortexyme analyst sentiment

The latest Cortexyme share price forecasts were presented on the day of the company’s update on its Alzheimer’s drug. 

Of the three analysts offering a price target on the day, Bank of America gave the most pessimistic outlook, downgrading the stock from ‘neutral’ to ‘underperform’ and lowering the price target from $58 to $15 – a 73.99% downside on the 27 October share price and closely tracking the 76.58% tumble that same day.

HC Wainwright cut its price target from $200 to $30. Canaccord Genuity halved their price target from $150 to $75. 

Cortexyme analyst ratings and price targets

Wallet Investor is one algorithm-based forecasting service offering a Cortexyme share price target for 2022-2025. 

The service projects a strong level of turbulence for the stock in 2022, before stabilising as it approaches $64 by 2025. The stock’s 2023 peak is forecast to be $51.81, rising to $62.05 in 2024.   

Note that price predictions can be wrong. Forecasts should not be used as a substitute for your own research. Always conduct your own due diligence before investing. And never invest or trade money you cannot afford to lose.  

FAQs

Is Cortexyme stock a good buy?

The stock has a ‘hold’ consensus recommendation based on five analysts’ views gathered by MarketBeat, with three analysts rating Cortexyme as a ‘buy’, one as a ‘hold’ and one giving a ‘sell’. 

Note that analyst forecasts can be wrong and should not be used as a substitute for your own research. Always conduct your own due diligence before investing. And never invest or trade money you cannot afford to lose.

Why has Cortexyme stock been going down?

Cortexyme fell by 76% on 27 October 2021 following disappointing clinical results on its Alzheimer’s drug Atuzaginstat and consequent analysts’ downgrades. The price fell below its IPO price of $17. It has failed to pick up momentum since, with little news to report and no other drugs in late-stage trials.

Will CRTX stock go up?

The average 12-month Cortexyme price target based on five analysts’ views gathered by MarketBeat currently sits at $38.50, ranging from the low of $15 to the high of $75.

There are a number of clinical risks that could continue to punish the stock in the near term before the company begins to return revenue.

Note that analyst forecasts can be wrong and should not be used as a substitute for your own research. Always conduct your own due diligence before investing. And never invest or trade money you cannot afford to lose.

Read more: UiPath (PATH) stock forecast: A bumpy road since IPO

Markets in this article

QNCX
Quince Therapeuticks Inc
0.9699 USD
0.0775 +9.080%

Rate this article

The difference between trading assets and CFDs
The main difference between CFD trading and trading assets, such as commodities and stocks, is that you don’t own the underlying asset when you trade on a CFD.
You can still benefit if the market moves in your favour, or make a loss if it moves against you. However, with traditional trading you enter a contract to exchange the legal ownership of the individual shares or the commodities for money, and you own this until you sell it again.
CFDs are leveraged products, which means that you only need to deposit a percentage of the full value of the CFD trade in order to open a position. But with traditional trading, you buy the assets for the full amount. In the UK, there is no stamp duty on CFD trading, but there is when you buy stocks, for example.
CFDs attract overnight costs to hold the trades (unless you use 1-1 leverage), which makes them more suited to short-term trading opportunities. Stocks and commodities are more normally bought and held for longer. You might also pay a broker commission or fees when buying and selling assets direct and you’d need somewhere to store them safely.
Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading